{"id":2264,"date":"2020-12-20T12:36:53","date_gmt":"2020-12-20T12:36:53","guid":{"rendered":"https:\/\/bibliography.nanobiotix.com\/?p=2264"},"modified":"2020-12-20T13:31:19","modified_gmt":"2020-12-20T13:31:19","slug":"2020-estro-nbtxr3-for-the-treatment-of-advanced-liver-cancers","status":"publish","type":"post","link":"https:\/\/bibliography.nanobiotix.com\/fr\/2020-estro-nbtxr3-for-the-treatment-of-advanced-liver-cancers\/","title":{"rendered":"2020 \u2013 ESTRO \u2013 NBTXR3 for the Treatment of Advanced Liver Cancers"},"content":{"rendered":"

[vc_row padding_top=\u00a0\u00bb0″ padding_bottom=\u00a0\u00bb0″ section_container_layout=\u00a0\u00bbfull-width\u00a0\u00bb remove_horizontal_padding=\u00a0\u00bbyes\u00a0\u00bb module_type=\u00a0\u00bbbg-color\u00a0\u00bb gutter_size=\u00a0\u00bbyes\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb bg_color=\u00a0\u00bb#28282e\u00a0\u00bb][vc_column][vc_row_inner padding_top=\u00a0\u00bb0″ padding_bottom=\u00a0\u00bb0″ gutter_size=\u00a0\u00bbyes\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb][vc_column_inner column_paddings=\u00a0\u00bb105″ column_position_vertical=\u00a0\u00bbmiddle\u00a0\u00bb column_min_height=\u00a0\u00bb700″ column_min_height_sm=\u00a0\u00bb400″ column_min_height_xs=\u00a0\u00bb350″ module_type=\u00a0\u00bbbg-image\u00a0\u00bb bg_image=\u00a0\u00bb102″ mask_fx=\u00a0\u00bbyes-mask\u00a0\u00bb mask_color_mode=\u00a0\u00bbpalette\u00a0\u00bb mask_bg_color_palette=\u00a0\u00bbmain-mask\u00a0\u00bb animation_fx=\u00a0\u00bbyes-animation\u00a0\u00bb animation_delay=\u00a0\u00bb200″ animation_offset_scroll_down=\u00a0\u00bb90″ width=\u00a0\u00bb1\/2″ animation_in=\u00a0\u00bbfadeInUp\u00a0\u00bb][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb responsive_lg=\u00a0\u00bbhidden\u00a0\u00bb responsive_md=\u00a0\u00bbhidden\u00a0\u00bb][az_box_icons box_icon_title=\u00a0\u00bbAuthors\u00a0\u00bb box_icon_color_mode=\u00a0\u00bbon-the-fly\u00a0\u00bb icon_visibility=\u00a0\u00bbyes-icon\u00a0\u00bb icon_type=\u00a0\u00bbfont\u00a0\u00bb icon=\u00a0\u00bbfa fa-edit\u00a0\u00bb icon_color_mode=\u00a0\u00bbon-the-fly\u00a0\u00bb icon_size=\u00a0\u00bb50″ box_icon_color=\u00a0\u00bb#ffffff\u00a0\u00bb icon_color=\u00a0\u00bb#ffffff\u00a0\u00bb]Thierry de Ba\u00e8re1<\/span>, Marc Pracht2<\/span>, Yann Rolland2<\/span>, J\u00e9r\u00f4me Durand-Labrunie1<\/span>, France Nguyen1<\/span>, Jean-Pierre Bronowicki3<\/span>, V\u00e9ronique Vendrely4<\/span>, Antonio Sa Cunha5<\/span>, Val\u00e9rie Crois\u00e9-Laurent3<\/span>, Emanuel Rio6<\/span>, Samuel Le Sourd2<\/span>, Patricia Said8<\/span>, Pierre Gustin1<\/span>, Christophe Perret6<\/span>, Didier Peiffert7<\/span>, Eric Deutsch1<\/span>, Enrique Chajon2<\/span>
\n
\n1 \u2013 Institut Gustave Roussy, Villejuif, FR
\n2 \u2013 Centre Eugene \u2013 Marquis, Rennes, FR
\n3 \u2013 CHRU de Nancy \u2013 H\u00f4pital de Brabois, Vandoeuvre-l\u00e8s-Nancy, FR
\n4 \u2013 CHU de Bordeaux \u2013 H\u00f4pital Haut-L\u00e9v\u00eaque, Pessac, FR
\n5 \u2013 Centre H\u00e9pato-Biliaire Paul Brousse, Villejuif, FR
\n6 \u2013 Institut de canc\u00e9rologie de l’Ouest, Nantes, FR
\n7 \u2013 Radiotherapy, Institut de Canc\u00e9rologie de Lorraine, Nancy, FR
\n8 \u2013 Nanobiotix, SA, Paris, FR
\n<\/span>[\/az_box_icons][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb responsive_lg=\u00a0\u00bbhidden\u00a0\u00bb responsive_md=\u00a0\u00bbhidden\u00a0\u00bb][\/vc_column_inner][vc_column_inner column_paddings=\u00a0\u00bb105″ column_position_vertical=\u00a0\u00bbmiddle\u00a0\u00bb module_type=\u00a0\u00bbbg-color\u00a0\u00bb animation_fx=\u00a0\u00bbyes-animation\u00a0\u00bb animation_delay=\u00a0\u00bb300″ animation_offset_scroll_down=\u00a0\u00bb90″ width=\u00a0\u00bb1\/2″ bg_color=\u00a0\u00bb#ffffff\u00a0\u00bb animation_in=\u00a0\u00bbfadeInUp\u00a0\u00bb][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb responsive_lg=\u00a0\u00bbhidden\u00a0\u00bb responsive_md=\u00a0\u00bbhidden\u00a0\u00bb][az_box_icons box_icon_title=\u00a0\u00bbSummary\u00a0\u00bb icon_visibility=\u00a0\u00bbyes-icon\u00a0\u00bb icon_type=\u00a0\u00bbfont\u00a0\u00bb icon=\u00a0\u00bbaz-icon az-icon-layers2″ icon_color_mode=\u00a0\u00bbon-the-fly\u00a0\u00bb icon_color=\u00a0\u00bb#28282e\u00a0\u00bb icon_size=\u00a0\u00bb50″]Purpose\/Objective:<\/strong> The use of stereotactic body radiotherapy (SBRT) for the local control of unresectable hepatocellular carcinoma (HCC) or liver metastases (mets) is well tolerated but limited by the need to preserve liver function. Increasing energy deposit within the tumor without increasing toxicity in healthy tissues remains a major challenge in radiation oncology. NBTXR3 (hafnium oxide nanoparticles), a first-in-class radioenhancer when activated by RT augments energy dose deposit within tumor cells, increasing tumor cell death compared to RT alone, while sparing healthy tissues.\u00a0Patients (pts) with HCC or mets may benefit from the mode of action of NBTXR3. A phase I\/II clinical trial has been conducted to evaluate NBTXR3 activated by SBRT in these pts [NCT02721056].<\/p>\n

Material\/Methods:<\/strong> The Phase I is a 3+3 dose escalation scheme with 5 NBTXR3 dose levels: 10, 15, 22, 33, and 42% of baseline tumor volume. NBTXR3 has been administered by intratumoral injection (ITI) followed by SBRT (45 Gy \/ 3 fractions \/ 5 to 7 days or 50 Gy \/ 5 fractions \/ 15 days). Primary endpoints were determination of the RP2D and early DLTs. Secondary endpoints included the safety profile, liver disease scores evolution, and early efficacy by response rate (mRECIST\/RECIST 1.1).<\/p>\n

Results:<\/strong> Twenty pts have been treated. The dose levels of 10, 15, 22 and 33% are completed: 6 pts at 10% (2 SBRT doses tested due to organ constraints), 4 pts each at 15% and 22% (due to fiducial displacement and ITI shift) and 3 pts at 33%. The final (42%) dose escalation level is ongoing with 3 pts treated thus far. No early DLT has been observed. One SAE (G3 bile duct stenosis) related to NBTXR3 and RT occurred at the 22% dose level. Adverse events related to ITI or NBTXR3 were: G2 malaise at the 10% dose level, 2 G3 abdominal pain at 15%, G1 pleural effusion and G3 bile duct stenosis at 22% and G1 fatigue at 33%. No clinically meaningful changes in CPS and APRI were observed post-treatment and CT-scan showed no leakage of NBTXR3 into surrounding healthy tissues. Best observed response in evaluable patients for HCC (n=8) were 5 CR, 3 PR and for mets (n=5) the results were: 4 PR, 1 SD.<\/p>\n

Conclusion:<\/strong> Intratumoral injection of NBTXR3 is feasible, demonstrated a very good safety and tolerability profile up to the 42% dose level. Recruitment at the 42% dose level is nearly finalized. Early efficacy results suggest NBTXR3 has the potential to address an unmet medical need in pts with unresectable primary or metastatic liver cancer.[\/az_box_icons][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb responsive_lg=\u00a0\u00bbhidden\u00a0\u00bb responsive_md=\u00a0\u00bbhidden\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/section>","protected":false},"excerpt":{"rendered":"

The use of stereotactic body radiotherapy (SBRT) for the local control of unresectable hepatocellular carcinoma (HCC) or liver metastases (mets) is well tolerated but limited by the need to preserve liver function. Increasing energy deposit within the tumor without increasing toxicity in healthy tissues remains a major challenge in radiation oncology. NBTXR3 (hafnium oxide nanoparticles), a first-in-class radioenhancer when activated by RT augments energy dose deposit within tumor cells, increasing tumor cell death compared to RT alone, while sparing healthy tissues. [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":2280,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[182,183,669],"tags":[349,620],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/posts\/2264"}],"collection":[{"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/comments?post=2264"}],"version-history":[{"count":2,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/posts\/2264\/revisions"}],"predecessor-version":[{"id":2326,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/posts\/2264\/revisions\/2326"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/media\/2280"}],"wp:attachment":[{"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/media?parent=2264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/categories?post=2264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/tags?post=2264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}